Human Mesothelin PE-conjugated Antibody Summary
Glu296-Gly580
Accession # AAH09272
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of Mesothelin in HeLa Human Cell Line by Flow Cytometry. HeLa human cervical epithelial carcinoma cell line was stained with Rat Anti-Human Mesothelin PE‑conjugated Monoclonal Antibody (Catalog # FAB32652P, filled histogram) or isotype control antibody (Catalog # IC006P, open histogram). View our protocol for Staining Membrane-associated Proteins.
View Larger
Mesothelin Specificity is Shown by Flow Cytometry in Knockout Cell Line. Mesothelin knockout HeLa human cervical epithelial carcinoma cell line was stained with Rat Anti-Human Mesothelin PE-conjugated Monoclonal Antibody (Catalog # FAB32652P, filled histogram) or isotype control antibody (Catalog # IC006P, open histogram). No staining in the Mesothelin knockout HeLa cell line was observed. View our protocol for Staining Membrane-associated Proteins.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: Mesothelin
Mesothelin is a 40 kDa glycosylphosphatidylinositol-anchored glycoprotein that is expressed on mesothelial cells in the pleura, pericardium and peritoneum and overexpressed in mesotheliomas and ovarian or pancreatic adenocarcinoma. Mesothelin is a product of the CAK-1 gene, which also encodes megakaryocyte-potentiating factor (MPF). Mature human mesothelin shares 60% amino acid identity with either mouse or rat mesothelin. Two variant forms exist; variant 1 has an eight amino acid (1 kDa) insertion and is rarely expressed, while variant 2 is a truncated form secreted in the majority of ovarian cancers but rarely found in normal individuals.
Product Datasheets
Citations for Human Mesothelin PE-conjugated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
13
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy
Authors: Shipra Das, Julien Valton, Philippe Duchateau, Laurent Poirot
Frontiers in Immunology
-
Tumor-targeted non-ablative radiation promotes solid tumor CAR T-cell therapy efficacy
Authors: Quach, HT;Skovgard, MS;Villena-Vargas, J;Bellis, RY;Chintala, NK;Amador-Molina, A;Bai, Y;Banerjee, S;Saini, J;Xiong, Y;Vista, WR;Byun, AJ;De Biasi, A;Zeltsman, M;Mayor, M;Morello, A;Mittal, V;Gomez, DR;Rimner, A;Jones, DR;Adusumilli, PS;
Cancer immunology research
Species: Mouse
Sample Types: Whole Cells
Applications: CAR-T (Flow Cytometry) -
Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity
Authors: YR Li, J Brown, Y Yu, D Lee, K Zhou, ZS Dunn, R Hon, M Wilson, A Kramer, Y Zhu, Y Fang, L Yang
Cancers, 2022-06-01;14(11):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy
Authors: YR Li, Y Yu, A Kramer, R Hon, M Wilson, J Brown, L Yang
Cells, 2022-05-08;11(9):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
CRISPR/Cas9-mediated TGFbetaRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro
Authors: K Alishah, M Birtel, E Masoumi, L Jafarzadeh, HR Mirzaee, J Hadjati, RH Voss, M Diken, S Asad
Journal of Translational Medicine, 2021-11-27;19(1):482.
Species: Human
Sample Types: Whole Cells
Applications: ICC -
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Authors: M Zhang, JL Luo, Q Sun, J Harber, AG Dawson, A Nakas, S Busacca, AJ Sharkey, D Waller, MT Sheaff, C Richards, P Wells-Jord, A Gaba, C Poile, EY Baitei, A Bzura, J Dzialo, M Jama, J Le Quesne, A Bajaj, L Martison, JA Shaw, C Pritchard, T Kamata, N Kuse, L Brannan, P De Philip, H Yang, G Griffiths, G Wilson, C Swanton, F Dudbridge, EJ Hollox, DA Fennell
Nature Communications, 2021-03-19;12(1):1751.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells
Authors: E Masoumi, L Jafarzadeh, HR Mirzaei, K Alishah, K Fallah-Meh, H Rostamian, M Khakpoor-K, R Meshkani, F Noorbakhsh, J Hadjati
J. Exp. Clin. Cancer Res., 2020-03-10;39(1):49.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
Authors: E Zhang, P Yang, J Gu, H Wu, X Chi, C Liu, Y Wang, J Xue, W Qi, Q Sun, S Zhang, J Hu, H Xu
J Hematol Oncol, 2018-08-13;11(1):102.
Species: Human
Sample Types: Transfected Whole Cells
Applications: Flow Cytometry -
High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients
Authors: Y Tang, Z Wang, Z Li, J Kim, Y Deng, Y Li, JR Heath, W Wei, S Lu, Q Shi
Proc. Natl. Acad. Sci. U.S.A, 2017-02-21;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
J Clin Invest, 2016-07-25;126(8):3130-44.
Species: Human
Sample Types: Whole Cells
Applications: CAR-T (Flow Cytometry) -
An in vivo platform for tumor biomarker assessment.
Authors: Servais EL, Suzuki K, Colovos C
PLoS ONE, 2011-10-26;6(10):e26722.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
An NK-like CAR T cell transition in CAR T cell dysfunction
Authors: Charly R. Good, M. Angela Aznar, Shunichiro Kuramitsu, Parisa Samareh, Sangya Agarwal, Greg Donahue et al.
Cell
-
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
Authors: Eva J. ter Weele, Anton G.T. Terwisscha van Scheltinga, Jos G.W. Kosterink, Linda Pot, Silke R. Vedelaar, Laetitia E. Lamberts et al.
Oncotarget
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human Mesothelin PE-conjugated Antibody
Average Rating: 3 (Based on 2 Reviews)
Have you used Human Mesothelin PE-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Isotype: PE-Rat IgG2a
The antibody worked as expected for all the cell lines tested except for NCI-H226.
